摘要
建桐翁正【摘要】目的验证和比较哌泊噻嗪、氟哌啶醇癸酸酯、氟奋乃静癸酸酯三种长效抗精神病制剂对精神分裂症的疗效及副反应。方法采用多中心、开放随机对照研究，以简明精神病评定量表（ＢＰＲＳ）、阳性症状评定量表（ＳＡＰＳ）、阴性症状评定量表（ＳＡＮＳ）、临床疗效总评量表（ＣＧＩ）和副反应量表（ＴＥＳＳ）、锥体外系副反应量表（ＲＳＥＳＥ）综合评定。结果治疗后哌泊噻嗪组患者的ＣＧＩＳＩ与ＣＧＩＧＩ分值和ＳＡＮＳ量表总分均低于其它两组，差异均有显著性（Ｐ＜０．０５），而ＢＰＲＳ和ＳＡＰＳ量表总分治疗结束时三组间差异无显著性（Ｐ＞０．０５）。ＴＥＳＳ总分和ＲＳＥＳＥ总分在整个治疗过程中均以氟奋乃静癸酸酯组最高，哌泊噻嗪组最低。结论三组中以哌泊噻嗪对精神分裂症的疗效较好，对阴性症状的改善优于氟哌啶醇癸酸酯组和氟奋乃静癸酸酯组，对阳性症状的疗效近似。哌泊噻嗪组副反应较少。
Objective The study compared the efficacy and safety of pipotiazine palmitate, haloperidol decanota and flupenthixol decanota in the treatment of schizophrenic patients. Methods The study was a multicenter open controlled trial. The clinical efficacy was assessed by Brief Psychiatry Rating Scale (BPRS), Scale for Assessment of Positive Symptoms (SAPS), Scale for Assessment of Negative Symptoms (SANS), Clinical Global Impression (CGI), and Treatment Emergent Symptom Scale (TESS) and RSESE were used to evaluate the side effects. Results The scores of CGI SI, CGI GI and total score of SANS after pipotiazine palmitate were the lowest among the three groups, and the differences were significant. While no significant difference in the total scores of BPRS and SAPS in three groups was found after the treatment. The scores of TESS and RSESE were highest in flupenthixol decanota group and lowest in pipotiazine palmitate group. Conclusion The clinical efficacy and safety of pipotiazine palmitate was the best among the three drugs, especially in improving of negative symptoms.
出处
《中华精神科杂志》
CSCD
1998年第4期218-221,共4页
Chinese Journal of Psychiatry
